%0 Journal Article %A fallah, shahrzad %A Sobouti, behnam %T Meningococcal Vaccine %J Clinical Excellence %V 8 %N 1 %U http://ce.mazums.ac.ir/article-1-390-en.html %R %D 2018 %K Vaccine, Meningococcal, Neisseria meningitidis., %X Neisseria meningitidis has 13 clinically significant serogroups, classified according to the antigenic structure of their polysaccharide capsule. Six serogroups, A, B, C, Y, W-135, and X, are responsible for virtually all cases of the disease in humans. Quadrivalent (Serogroups A, C, W-135, and Y) There are currently three vaccines available in the US to prevent meningococcal disease, all quadrivalent in nature, targeting serogroups A, C, W-135, and Y: Two conjugate vaccines (MCV-4), Menactra and Menveo, and One polysaccharide vaccine (MPSV-4), Menomune, produced by Sanofi Pasteur. Bivalent (Serogroups C and Y): On 2012, the FDA approved a new combination vaccine against two types of meningococcal disease and Hib disease for infants and children 6 weeks to 18 months old. The vaccine, Menhibrix, will prevent disease caused byNeisseria meningitidis serogroups C and Y and Haemophilus influenzae type b. This is the first meningococcal vaccine that can be given to infants as young as six weeks old. Serogroup A: A vaccine called MenAfriVac has been developed through a program called the Meningitis Vaccine Project and has the potential to prevent outbreaks of group A meningitis. Serogroup B: Vaccines against serotype B meningococcal disease have proved difficult to produce, and require a different approach from vaccines against other serotypes. Serogroup X: The occurrence of serogroup X has been reported in North America, Europe, Australia, and West Africa. Current meningoccocal meningitis vaccines are not known to protect against serogroup X N. meningitidis disease. Side effects of the vaccine include: Common side effects include pain and redness around the site of injection (up to 50% of recipients). A small percentage of people develop a mild fever. As with any medication, a small proportion of people develop a severe allergic reaction. The highest risk was when individuals received a dose of Soliris within 2 weeks after being vaccinated with Bexsero. %> http://ce.mazums.ac.ir/article-1-390-en.pdf %P 7-8 %& 7 %! %9 Review %L A-10-26-57 %+ Iran university of medical sciences %G eng %@ 2322-391x %[ 2018